Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes.
Martin J et al.
Diabetes Care. 2006;29:1826-32.
37 subjects with type 2 diabetes mellitus receiving sulfonylurea therapy were provided with chromium supplementation (1000 microg chromium/day provided as chromium picolinate) or placebo daily for 6 months. Compared with sulfonylurea/placebo, sulfonylurea/CrPic significantly improved insulin sensitivity and glucose control, and significantly attenuated body weight gain and visceral fat accumulation.
Phenotype of subjects with type 2 diabetes mellitus may determine clinical response to chromium supplementation.
Wang ZQ et al.
Metabolism. 2007;56:1652-5.
Subject phenotype appears to be very important when assessing the clinical response to chromium. In this study, 73 subjects with type 2 diabetes mellitus received chromium supplementation (1000 microg chromium/day provided as chromium picolinate) or placebo daily for 6 months. Clinical response rates were 63% with chromium group versus 30% with placebo. Baseline insulin sensitivity (as assessed with the hyperinsulinaemic-euglycaemic clamp) was the only subject variable significantly associated with the clinical response to chromium.
The effect of chromium picolinate and biotin supplementation on glycemic control in poorly controlled patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized trial.
Singer GM and Geohas J.
Diabetes Technol Ther. 2006;8:636-43.
Supplementation for 4 weeks with a combination of 600 microg of chromium as chromium picolinate and biotin (2 mg/day) in 43 poorly controlled patients with type 2 diabetes mellitus receiving antidiabetic therapy improved glucose management and several lipid measurements.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment